ACRV · Acrivon Therapeutics, Inc.
AI read · Neutral
The AI's read
The deck offers an early lab finding: it says ACR-2316 caused complete tumor regression in preclinical models. But lab results do not show whether a drug helps people. The supplied filing gives no patient response or safety figures, so it does not establish a clear change in Acrivon’s prospects.